Thromb Haemost 2006; 95(02): 312-319
DOI: 10.1160/TH05-06-0458
Endothelium and Vascular Development
Schattauer GmbH

Endothelial cells express a matrix protein which binds activated factor XII in a zinc-independent manner

Inger Schousboe
1   Department of Medical Biochemistry and Genetics, The Panum Institute, University of Copenhagen, Denmark
› Author Affiliations
Financial support: The work was supported by a grant from the Novo Nordisk Foundation.
Further Information

Publication History

Received 30 June 2005

Accepted after revision 17 January 2005

Publication Date:
28 November 2017 (online)

Summary

Recent studies have shown that peptides identified as surface binding regions of high molecular mass kininogen (HK) and factor XII (FXII) inhibit the Zn2+-dependent binding of FXII to confluent layers of human umbilical vein endothelial cells (HUVEC). This indicates that negatively charged FXII binding surfaces, such as sulfatides and dextran sulfate, may interfere with the binding of FXII to confluent layer of HUVEC. Upon investigating this hypothesis it was unexpectedly found that sulfatides enhanced a specific binding of FXII to a matrix protein expressed during growth of the endothelial cells and that this binding was independent of the presence of Zn2+. The function of sulfatides was partly to minimize nonspecific electrostatic binding and partly to induce and enhance autoactivation of FXII generating αFXIIa. Western blot analysis of the extracts of the matrix incubated with FXII and sulfatides showed that the binding was specific for αFXIIa. The dissociation constant for binding αFXIIa was 12. 8 ± 0. 4 nM (n=4). The binding of αFXIIa to ECM was mapped to the heavy chain as no binding was observed of the light chain containing the catalytic domain. HK, which previously has been shown to completely abolish the Zn2+-dependent binding of FXII to confluent layers of HUVEC, did not inhibit the binding of αFXIIa to the matrix but sulfatides enhanced binding of FXII to ECM. This suggests that HK interferes with the binding of FXII to sulfatides and thereby the autoactivation of FXII. Trypsin treatment of the matrix protein completely abolished the binding, and fibronectin but not laminin was found to bea suitable target. The binding of activated FXII to the ECM suggests that FXIIa may bea modulator of cellular adhesion, migration and vascularization.

 
  • References

  • 1 Reddigari SR, Shibayama YS, Brunnée T. et al. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 1993; 268: 11982-7.
  • 2 Schousboe I. Rapid and cooperative binding of factor XII to human umbilical vein endothelial cells. Eur J Biochem 2001; 268: 3958-63.
  • 3 Røjkjær R, Hasan AA, Motta G. et al. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 1998; 80: 74-81.
  • 4 Joseph K, Shibayama Y, Ghebrehiwet B. et al. Factor XII-dependent contact activation on endothelial cells and binding proteins gC1qR and cytokeratin 1. Thromb Haemost 2001; 85: 119-24.
  • 5 Joseph K, Ghebrehiwet B, Peerschke EI. et al. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: Identity with the receptor that binds to the globular heads of C1q (gC1q-R). Proc Natl Acad Sci USA 1996; 93: 8552-7.
  • 6 Hasan AA, Zisman T, Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci USA 1998; 95: 3615-20.
  • 7 Joseph K, Ghebrehiwet B, Kaplan AP. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin Immunol 1999; 92: 246-55.
  • 8 Mahdi F, Madar ZS, Figueroa CD. et al. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002; 99: 3585-96.
  • 9 Citarella F, te Velthuis H, Helmer-Citterich M. et al. Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII. An immunochemical and homology modeling approach. Thromb Haemost 2000; 84: 1057-65.
  • 10 Tans G, Rosing J, Griffin JH. Sulfatide-dependent autoactivation of human blood coagulation factor XII (Hageman Factor). J Biol Chem 1983; 258: 8215-22.
  • 11 Schousboe I. Contact activation on human plasma is triggered by zinc ion modulation of factor XII (Hageman factor). Blood Coag Fibrinol 1993; 04: 671-8.
  • 12 Bernardo MM, Day DE, Olson ST. et al. Surface-independent acceleration of factor XII activation by zinc ions: Direct binding and fluorescence studies. J Biol Chem 1993; 268: 12477-83.
  • 13 Røjkjær R, Schousboe I. The surface-dependent autoactivation mechanism of factor XII. Eur J Biochem 1997; 243: 160-6.
  • 14 Sud’ina GF, Brock TG, Pushkareva MA, Galkina SI, Turutin DV, Peters-Golden M, Ullrich V. Sulfatides trigger polymorphonuclear granulocyte spreading on collagen-coated surfaces and inhibit subsequent activation of 5-lipoxygenase. Biochem J 2001; 359: 621-9.
  • 15 Roberts DD, Rao CN, Magnani JL. et al. Laminin binds specifically to sulfated glycolipids. Proc Natl Acad Sci USA 1985; 82: 1306-10.
  • 16 Pixley RA, Schapoira M, Colman RW. The regulation of human factor FXIIa by plasma proteinase inhibitors. J Biol Chem 1985; 260: 1723-9.
  • 17 Schousboe I, Thomsen P, van Deurs B. Factor XII binding to endothelial cells depends on caveolae. Eur J Biochem 2004; 271: 2998-3005.
  • 18 Wanaski SP, Ng BK, Glaser M. Caveolin scaffolding region and the memrane bnding region of SRC form lateral membrane domains. Biochemistry Biochemistry 2003; 42: 42-5.
  • 19 Jiang J, Serinkan BF, Tyurina YY. et al. Peroxidation and externalization of phosphotidylserine associated with release of cytochromeC from mitochondria. Free Radic Biol Med 2003; 35: 814-25.
  • 20 Hara A, Taketomi T. Occurrence of sulfatide as a major glycoshingolipid in WHHL rabbit serum lipoproteins. J Biochem (Tokyo) 1987; 102: 83-92.
  • 21 Roberts DD, Ginsburg V. Sulfated glycolipids and cell adhesion. Arch Biochem Biophys 1988; 267: 405-15.
  • 22 Kushi Y, Arita M, Ishizuka I. et al. Sulfatide is expressed in both erythrocytes and platelets of bovine origin. Biochim Biophys Acta 1996; 1304: 254-62.
  • 23 Roberts DD, Haverstick DM, Dixit VM. et al. The platelet glycoprotein thrombospondin binds specifically to sulfated glycolipids. J Biol Chem 1985; 260: 9405-11.
  • 24 Aruffo K, Kolanus W, Walch G. et al. CD62/P-selection recognition of myeloid and tumor cell sulfatides. Cell 1991; 67: 35-44.